‘REMISSION 1℃’ expected to be a ‘game changer’ in COVID-19 treatment

Clinical results yielded a CT value of 32 or higher... ‘Electronic drug’ research expected to lead to new milestones

Overseas response fast to the effectiveness of COVID-19 treatment… Requests for support flooded from over 10 countries

As the COVID-19 pandemic continues, a new weapon(?) that can treat COVID-19 patients in Korea has emerged and is capturing spotlight.

In particular, as the government is known to be planning a With Corona program starting in November, high-frequency hyperthermia therapy has been proven to be effective in treating COVID-19 patients and is expected to be a ‘game changer’ in the treatment of COVID-19.

In addition, the International Virus Research Alliance (IVRA), an international collaborative for the treatment of COVID-19, was formed, and research on high frequency hyperthermia treatment for COVID-19 appears to have been actively conducted.

▲ International conference to conquer the COVID-19 pandemic held at COEX on September 29th.

IVRA composition… Presenting a new paradigm for treatment

IVRA held an international conference at COEX on September 29th and attracted attention by presenting a new medical paradigm centered on the efficacy of ‘immune treatment’ ahead of With Corona.

This conference will be attended by ambassadors and commercial attachés from over 30 countries around the world, as well as leading medical officials at home and abroad, to discover treatments by applying the principle that ‘hyperthermia treatment is effective for viral infections’ and to treat positive patients with COVID-19 and prevent severe cases. Members exchanged various ways to prevent the disease, sharing the latest knowledge.

IVRA is an organization of medical experts formed to exchange joint research results and information among members to solve national problems by collaborating with various countries, including China, India, Malaysia, Singapore, Kazakhstan, and the Philippines, to end the COVID-19 pandemic.

In the future, IVRA plans to increase the number of cases based on well-designed protocols with the results obtained through sharing treatment data and continue research with international scholars.

On this day, prior to the international conference, the appointment ceremony for the first IVRA organizing committee chairperson was held. Chairman Yoo Seung-mo (Chairman of the Health and Healthcare Subcommittee of the Chungnam Regional Economic and Diplomacy Strategy Committee) and Professor Lee Kang-hyeon of Yonsei University Wonju University (former Dean of Yonsei University Wonju University) were appointed as the first organizing committee chairs of IVRA.

Additionally, about 50 advisory members were appointed including former Dankook University Medical Center Director Park Woo-sung (Chairman of the Cancer Center Promotion Committee), Catholic University School of Medicine Professor Jang Hong-seok, Yonsei University Wonju University Professor Hwang Seong-oh, Catholic University School of Medicine Professor Kang Young-nam, Chung-Ang University Medical School Professor Jeong Yun-jae, Soonchunhyang University School of Medicine Professor Kim Ho-jung, and Kyung Hee University School of Medicine Professor Lee Hyeong-min.

▲ AdipoLABs high-frequency hyperthermia device REMISSION 1℃.

‘REMISSION 1°C’ clinical results create ‘attention’

In particular, at the conference on this day, Professor Jang Hong-seok's team from the Advanced Convergence Research Institute of Seoul St. Mary's Hospital and Seosan Medical Center announced the results of treating COVID-19 patients using the high-frequency hyperthermia device 'REMISSION 1℃' provided by AdipoLABs, drawing great attention from around the world.

In this study using the high-frequency hyperthermia device ‘REMISSION 1℃’, two Philippino men were treated with a PCR test after using the high-frequency device twice over two days, and the results were negative.

Especially, as a result of measuring CT values before and after treatment for 20 domestic patients, the average value of the E gene increased from 23.66 before treatment to 32.63 after treatment, the average value of the RdRP S gene increased from 24.07 before treatment to 33.18 after treatment, and the average value of the N gene increased from 24.07 before treatment to 33.18 after treatment. Statistically significant results were obtained, with the average value before treatment increasing from 25.22 to 33.24 after treatment.

Regarding this clinical trial, IVRA Chairman Yoo Seung-mo said, “If two of the three test reagents test 30 or higher, a COVID-19 patient can be discharged.”

In addition, Chairman Yoo said, “Internationally, if it is 29.5 or higher, it should be considered negative and not harmful to others.” He added, “These results can reduce the loss of precious lives and economic losses by quickly treating patients with mild symptoms in the early stages of viral infection before it spreads to severe disease.” “And furthermore, it is the only key that can make With Corona possible,” he emphasized. In particular, he emphasized, “We will be able to create a new turning point through research using electromedicine.”

Requests for support from 10 countries, including Singapore

After the international conference, overseas reactions related to COVID-19 treatment using high-frequency hyperthermia devices are heating up.

According to an AdipoLABs official, this conference served as an opportunity to spread interest in Korean medical devices to governments and scholars around the world, and numerous inquiries are being received.

Particularly, Malaysia, which is currently using the high-frequency hyperthermia therapy device 'REMISSION 1℃' for cancer treatment at UMMC Hospital, plans to actively use this opportunity to treat COVID-19 patients, and 10 countries including Honduras, Romania, Singapore, and Mauritius participated in this event. Requests for support and cooperation have been received from several countries.

▲ CEO Han Sung-ho.

Han Sung-ho, CEO of AdipoLABs, said, “We are satisfied that hyperthermia therapy has achieved meaningful results in treating the COVID-19 virus by increasing immunity, and I hope this will give us an opportunity to prove the effectiveness of immunotherapy for many patients infected with the virus through support policies in each country.” he said.

In particular, he emphasized, “We will contribute to ending the global COVID-19 pandemic by providing high-frequency hyperthermia device REMISSION 1℃ free of charge to member countries so that the results of this experiment can be experienced overseas.”

AdipoLABs “Free support plan for member countries”

Meanwhile, a high-frequency hyperthermia device transmits high frequencies to the human body and raises the core temperature of the human body to over 40℃ through ion friction of the body, promoting blood circulation and improving immunity. It not only treats inflammation and virus-infected cells and cancer that are vulnerable to heat, but also relieves pain. As a palliative medical device, REMISSION 1℃ was approved as an official medical device by the Ministry of Food and Drug Safety in 2015 and is being used to treat numerous patients at home and abroad.

As a matter of fact, under the judgment of the medical community that when deep fever occurs through high frequency waves, NK cells, our body's autoimmune cells, are activated to the highest level and can catch the virus, doctors treat patients infected with COVID-19 with the confidence that they can also catch COVID-19.